Placeholder Banner

A Patient Advocate’s Perspective on Foreign Price Controls

February 7, 2020
Media Contact
Author-Profile-Andrew-Segerman

In a new video, Cynthia Bens, patient advocate and Senior Vice President of Public Policy at the Personalized Medicine Coalition, shares her views on how adopting foreign price controls for prescription medicines will impact patients in the U.S.

 

“I wouldn’t say the President’s proposal for reference pricing is the right way to deal with drug pricing issues. We need to look at the problem holistically. …
 
“What’s really challenging, right now, is all of the estimates on what the president’s foreign reference pricing proposal really means for patients is that there’s going to be a reduction in research and development. …
 
“The harms of the foreign reference pricing proposal really outweigh the benefits that patients are going to see.” 


To learn more about the flaws of importing foreign price controls, visit bio.org/save-cures.


###
 

Discover More
The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating Covid-19. The two-day virtual…
Companies are Coming Together to Achieve Shared Goal of Eradicating the Virus  Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment…
The Securities and Exchange Commission (SEC) has adopted regulatory changes to provide small public companies with a temporary exemption from Sarbanes-Oxley 404(b) compliance. 404(b) requires public companies to report on the internal controls they…